TriangleBRiTE (NCT04903795)
BRiTE trial for Newly Diagnosed Glioblastoma (NCT04903795). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Immune therapies that work elsewhere have failed in glioblastoma, partly because so few T cells ever reach the tumor.
The idea: a molecule that grabs a T cell with one hand and a tumor cell with the other.
A third of glioblastomas carry EGFRvIII, a mutant receptor found only on tumor cells. At Duke, a bispecific T cell engager binds EGFRvIII on one arm and CD3 on T cells with the other, forcing the two together so the T cell kills. Because the molecule clears quickly, it is infused continuously for four days in each four-week cycle.
BRiTE is a first dose-finding study in adults whose tumors test positive, newly diagnosed or recurrent. The Duke BRiTE team runs it. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.